pressreleaseWednesday, September 25, 2013
Stockholm-Uppsala Life Science Investment Hotlist is growing. 15 new
companies enter the list, and take part in the search for international investments
“In our efforts to make this region
more accessible for life science investors, it is satisfying that we now can
greet 15 new exciting companies to Stockholm-Uppsala Life Science Investment
Hotlist. These are some of the most promising new companies in the sector. We
look forward to a busy period.” said Ylva Hultman-Erlandsson, business
development manager for life science at Stockholm Business Region Development.
The list has been prepared in collaboration
with the consulting firm Avanture and 35 companies are currently included. It
is established as a tool for investors, making it easier to find the gems of
the region. Foreign investments and partnerships are promoted by creating
awareness of the list, and accompanying pitch book, via investor meetings and
“We can summarize a very positive
first half-year, with almost 100 investor meetings and five continuing negotiations.
There is a considerable interest in the region. The
list does the groundwork for investors looking for opportunities.” said Ylva
To qualify, companies accepted on the
list must offer a product or service, based on unique research, which will lead
to a commercial solution with global potential. They must also have established
themselves on the market with a finished product or service, alternatively, be
close to the commercialization phase.
The selected companies are:
BioChromix, CathPrint, Gradientech, Scandinavian Biopharma, SciBase, SensAbues,
Dilafor, Glucox Biotech, Mando Group, Hoa’s Tool Shop, Infogosoft and SciLife Clinic.
Click here for the complete list and more
Click to tweet.
For more information
Per Holmlund, PR Manager, Stockholm
+46 70-472 80 69, email@example.com